Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DiscoveRx Corporation Continues to Innovate with Solutions for Epigenetic Drug Discovery Programs

Published: Monday, February 06, 2012
Last Updated: Monday, February 06, 2012
Bookmark and Share
The company announced availability of platform for studying Bromodomains, an emerging class of epigenetic targets.

The new platform designated as BROMOscan(TM), is based on the proven KINOMEscan(TM) technology and will enable high throughput screening, selectivity profiling and quantitative Kd determinations across several sub-families of bromodomains, including the BET family.

The platform enables screening for selective inhibitors of Bromodomain epigenetic "reader" proteins that bind and recognize acetylated lysine residues on histone tails, which are important epigenetic marks associated with gene expression and regulation. With many drug discovery programs aimed at identifying small molecules that inhibit Bromodomains, the availability of a quantitative and high-throughput platform represents a substantial leap forward and a powerful solution to support new discovery programs while supporting and expediting existing projects.

"With the recent understanding that epigenetics plays a pivotal role in inflammation and oncology, now more than ever the drug discovery community is seeking an enabling platform for high throughput screening of epigenetic targets," said Dr. Pyare Khanna, President & CEO of DiscoveRx. "Our goal was to leverage our in-house expertise platforms to build a high quality, first in class panel of Bromodomain ligand binding assays."

With over 25% coverage of the human bromodomain targets anticipated in the first panel, DiscoveRx extends its leadership position by offering screening and profiling solutions for key drug targets such as GPCRs, Kinases, NHRs and now epigenetic targets. This milestone achievement reaffirms DiscoveRx's continued commitment to invest in developing innovative products and solutions for the drug discovery community.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Validation of Drug Toxicity Prediction using DiscoveRx Model
BioMAP® Systems was shown to identify important safety aspects of drugs and chemicals more efficiently and accurately than can be achieved by animal testing.
Tuesday, May 20, 2014
DiscoveRx Corporation Acquires Bioseek
DiscoveRx adds primary cell assays to its portfolio of drug discovery solutions.
Thursday, November 08, 2012
DiscoveRx Expands its GPCR Technology Portfolio to Include Advanced Technologies
Introduces two additional GPCR platforms to facilitate counterscreening, lead optimization and SAR evaluation of compounds.
Friday, April 09, 2010
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!